Based on experimental evidences showing beneficial effects related to knockout of USP22 on tumor progression and to inhibition of acetylation we might envisage treatments with KAT and Ub-related inhibitors as active compounds counteracting tumor progression (Nebbioso et al., 2018). Here, USP22 is linked to neoplasm.